Selected research
Industry Research
P53 Antibody Industry Research Report 2026
Market perspective
The global P53 Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the P53 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the P53 Antibody market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the P53 Antibody market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of P53 Antibody include Thermo Fisher Scientific, Merck, Boster Biological Technology, United States Biological, Santa Cruz Biotechnology, Proteintech, NSJ Bioreagents, Miltenyi Biotec and Medimabs, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global P53 Antibody market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to P53 Antibody.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
P53 Antibody Market by Company
Thermo Fisher Scientific
Merck
Boster Biological Technology
United States Biological
Santa Cruz Biotechnology
Proteintech
NSJ Bioreagents
Miltenyi Biotec
Medimabs
Leica Biosystems
FineTest
EXBIO
Cell Signaling Technology
Bio-Rad
Beckman Coulter
Aviva Systems Biology
Atlas Antibodies
P53 Antibody Segment by Type
Polyclonal
Monoclonal
P53 Antibody Segment by Application
Immunohistochemistry
Immunocytochemistry
Immunoprecipitation
Enzyme Linked Immunosorbent Assay
Others
P53 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global P53 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of P53 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of P53 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of P53 Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Immunohistochemistry
- Immunocytochemistry
- Immunoprecipitation
- Enzyme Linked Immunosorbent Assay
- Others
Companies covered
- Thermo Fisher Scientific
- Merck
- Boster Biological Technology
- United States Biological
- Santa Cruz Biotechnology
- Proteintech
- NSJ Bioreagents
- Miltenyi Biotec
- Medimabs
- Leica Biosystems
- FineTest
- EXBIO
- Cell Signaling Technology
- Bio-Rad
- Beckman Coulter
- Aviva Systems Biology
- Atlas Antibodies
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 P53 Antibody by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Polyclonal
- 2.2.3 Monoclonal
- 2.3 P53 Antibody by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Immunohistochemistry
- 2.3.3 Immunocytochemistry
- 2.3.4 Immunoprecipitation
- 2.3.5 Enzyme Linked Immunosorbent Assay
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 P53 Antibody Breakdown Data by Type
- 3.1 Global P53 Antibody Historic Market Size by Type (2021-2026)
- 3.2 Global P53 Antibody Forecasted Market Size by Type (2027-2032)
4 P53 Antibody Breakdown Data by Application
- 4.1 Global P53 Antibody Historic Market Size by Application (2021-2026)
- 4.2 Global P53 Antibody Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global P53 Antibody Market Perspective (2021-2032)
- 5.2 Global P53 Antibody Growth Trends by Region
- 5.2.1 Global P53 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 P53 Antibody Historic Market Size by Region (2021-2026)
- 5.2.3 P53 Antibody Forecasted Market Size by Region (2027-2032)
- 5.3 P53 Antibody Market Dynamics
- 5.3.1 P53 Antibody Industry Trends
- 5.3.2 P53 Antibody Market Drivers
- 5.3.3 P53 Antibody Market Challenges
- 5.3.4 P53 Antibody Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top P53 Antibody Players by Revenue
- 6.1.1 Global Top P53 Antibody Players by Revenue (2021-2026)
- 6.1.2 Global P53 Antibody Revenue Market Share by Players (2021-2026)
- 6.2 Global P53 Antibody Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of P53 Antibody Head Office and Area Served
- 6.4 Global P53 Antibody Players, Product Type & Application
- 6.5 Global P53 Antibody Manufacturers Established Date
- 6.6 Global P53 Antibody Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America P53 Antibody Market Size (2021-2032)
- 7.2 North America P53 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America P53 Antibody Market Size by Country (2021-2026)
- 7.4 North America P53 Antibody Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe P53 Antibody Market Size (2021-2032)
- 8.2 Europe P53 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe P53 Antibody Market Size by Country (2021-2026)
- 8.4 Europe P53 Antibody Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific P53 Antibody Market Size (2021-2032)
- 9.2 Asia-Pacific P53 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific P53 Antibody Market Size by Country (2021-2026)
- 9.4 Asia-Pacific P53 Antibody Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America P53 Antibody Market Size (2021-2032)
- 10.2 South America P53 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America P53 Antibody Market Size by Country (2021-2026)
- 10.4 South America P53 Antibody Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa P53 Antibody Market Size (2021-2032)
- 11.2 Middle East & Africa P53 Antibody Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa P53 Antibody Market Size by Country (2021-2026)
- 11.4 Middle East & Africa P53 Antibody Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Thermo Fisher Scientific
- 12.1.1 Thermo Fisher Scientific Company Information
- 12.1.2 Thermo Fisher Scientific Business Overview
- 12.1.3 Thermo Fisher Scientific Revenue in P53 Antibody Business (2021-2026)
- 12.1.4 Thermo Fisher Scientific P53 Antibody Product Portfolio
- 12.1.5 Thermo Fisher Scientific Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in P53 Antibody Business (2021-2026)
- 12.2.4 Merck P53 Antibody Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 Boster Biological Technology
- 12.3.1 Boster Biological Technology Company Information
- 12.3.2 Boster Biological Technology Business Overview
- 12.3.3 Boster Biological Technology Revenue in P53 Antibody Business (2021-2026)
- 12.3.4 Boster Biological Technology P53 Antibody Product Portfolio
- 12.3.5 Boster Biological Technology Recent Developments
- 12.4 United States Biological
- 12.4.1 United States Biological Company Information
- 12.4.2 United States Biological Business Overview
- 12.4.3 United States Biological Revenue in P53 Antibody Business (2021-2026)
- 12.4.4 United States Biological P53 Antibody Product Portfolio
- 12.4.5 United States Biological Recent Developments
- 12.5 Santa Cruz Biotechnology
- 12.5.1 Santa Cruz Biotechnology Company Information
- 12.5.2 Santa Cruz Biotechnology Business Overview
- 12.5.3 Santa Cruz Biotechnology Revenue in P53 Antibody Business (2021-2026)
- 12.5.4 Santa Cruz Biotechnology P53 Antibody Product Portfolio
- 12.5.5 Santa Cruz Biotechnology Recent Developments
- 12.6 Proteintech
- 12.6.1 Proteintech Company Information
- 12.6.2 Proteintech Business Overview
- 12.6.3 Proteintech Revenue in P53 Antibody Business (2021-2026)
- 12.6.4 Proteintech P53 Antibody Product Portfolio
- 12.6.5 Proteintech Recent Developments
- 12.7 NSJ Bioreagents
- 12.7.1 NSJ Bioreagents Company Information
- 12.7.2 NSJ Bioreagents Business Overview
- 12.7.3 NSJ Bioreagents Revenue in P53 Antibody Business (2021-2026)
- 12.7.4 NSJ Bioreagents P53 Antibody Product Portfolio
- 12.7.5 NSJ Bioreagents Recent Developments
- 12.8 Miltenyi Biotec
- 12.8.1 Miltenyi Biotec Company Information
- 12.8.2 Miltenyi Biotec Business Overview
- 12.8.3 Miltenyi Biotec Revenue in P53 Antibody Business (2021-2026)
- 12.8.4 Miltenyi Biotec P53 Antibody Product Portfolio
- 12.8.5 Miltenyi Biotec Recent Developments
- 12.9 Medimabs
- 12.9.1 Medimabs Company Information
- 12.9.2 Medimabs Business Overview
- 12.9.3 Medimabs Revenue in P53 Antibody Business (2021-2026)
- 12.9.4 Medimabs P53 Antibody Product Portfolio
- 12.9.5 Medimabs Recent Developments
- 12.10 Leica Biosystems
- 12.10.1 Leica Biosystems Company Information
- 12.10.2 Leica Biosystems Business Overview
- 12.10.3 Leica Biosystems Revenue in P53 Antibody Business (2021-2026)
- 12.10.4 Leica Biosystems P53 Antibody Product Portfolio
- 12.10.5 Leica Biosystems Recent Developments
- 12.11 FineTest
- 12.11.1 FineTest Company Information
- 12.11.2 FineTest Business Overview
- 12.11.3 FineTest Revenue in P53 Antibody Business (2021-2026)
- 12.11.4 FineTest P53 Antibody Product Portfolio
- 12.11.5 FineTest Recent Developments
- 12.12 EXBIO
- 12.12.1 EXBIO Company Information
- 12.12.2 EXBIO Business Overview
- 12.12.3 EXBIO Revenue in P53 Antibody Business (2021-2026)
- 12.12.4 EXBIO P53 Antibody Product Portfolio
- 12.12.5 EXBIO Recent Developments
- 12.13 Cell Signaling Technology
- 12.13.1 Cell Signaling Technology Company Information
- 12.13.2 Cell Signaling Technology Business Overview
- 12.13.3 Cell Signaling Technology Revenue in P53 Antibody Business (2021-2026)
- 12.13.4 Cell Signaling Technology P53 Antibody Product Portfolio
- 12.13.5 Cell Signaling Technology Recent Developments
- 12.14 Bio-Rad
- 12.14.1 Bio-Rad Company Information
- 12.14.2 Bio-Rad Business Overview
- 12.14.3 Bio-Rad Revenue in P53 Antibody Business (2021-2026)
- 12.14.4 Bio-Rad P53 Antibody Product Portfolio
- 12.14.5 Bio-Rad Recent Developments
- 12.15 Beckman Coulter
- 12.15.1 Beckman Coulter Company Information
- 12.15.2 Beckman Coulter Business Overview
- 12.15.3 Beckman Coulter Revenue in P53 Antibody Business (2021-2026)
- 12.15.4 Beckman Coulter P53 Antibody Product Portfolio
- 12.15.5 Beckman Coulter Recent Developments
- 12.16 Aviva Systems Biology
- 12.16.1 Aviva Systems Biology Company Information
- 12.16.2 Aviva Systems Biology Business Overview
- 12.16.3 Aviva Systems Biology Revenue in P53 Antibody Business (2021-2026)
- 12.16.4 Aviva Systems Biology P53 Antibody Product Portfolio
- 12.16.5 Aviva Systems Biology Recent Developments
- 12.17 Atlas Antibodies
- 12.17.1 Atlas Antibodies Company Information
- 12.17.2 Atlas Antibodies Business Overview
- 12.17.3 Atlas Antibodies Revenue in P53 Antibody Business (2021-2026)
- 12.17.4 Atlas Antibodies P53 Antibody Product Portfolio
- 12.17.5 Atlas Antibodies Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst